BRPI0915627A8 - Compostos derivados de indol, composições farmacêuticas que os contêm, e seus usos - Google Patents
Compostos derivados de indol, composições farmacêuticas que os contêm, e seus usosInfo
- Publication number
- BRPI0915627A8 BRPI0915627A8 BRPI0915627A BRPI0915627A BRPI0915627A8 BR PI0915627 A8 BRPI0915627 A8 BR PI0915627A8 BR PI0915627 A BRPI0915627 A BR PI0915627A BR PI0915627 A BRPI0915627 A BR PI0915627A BR PI0915627 A8 BRPI0915627 A8 BR PI0915627A8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical compositions
- group
- compositions containing
- compounds
- derivative compounds
- Prior art date
Links
- -1 INDOL DERIVATIVE COMPOUNDS Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
COMPOSTOS DERIVADOS DE INDOL, COMPOSIÇÕES FARMACÊUTICAS QUE OS CONTÊM, E SEUS USOS. A presente invenção se refere a um composto derivado de indol, em especial terapeuticamente útil, que é selecionado dentre os compostos da fórmula (I), na qual: R1 representa um halogênio ou um grupo trifluorometil, R2 representa um átomo de hidrogênio ou um grupo alquila C1-C4, R3 representa um grupo isopropil (1-metiletil) ou um grupo tert-butil (1,1-dimetiletil), e n = 3 ou 4; e dentre sais farmaceuticamente aceitáveis dos referidos compostos da fórmula (I), para o tratamento de doenças neurodegenerativas e mais particularmente do mal de Parkinson.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0854712A FR2933609B1 (fr) | 2008-07-10 | 2008-07-10 | Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson. |
PCT/FR2009/051372 WO2010004221A2 (fr) | 2008-07-10 | 2009-07-09 | Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0915627A2 BRPI0915627A2 (pt) | 2016-07-26 |
BRPI0915627A8 true BRPI0915627A8 (pt) | 2017-05-16 |
Family
ID=40297845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0915627A BRPI0915627A8 (pt) | 2008-07-10 | 2009-07-09 | Compostos derivados de indol, composições farmacêuticas que os contêm, e seus usos |
Country Status (28)
Country | Link |
---|---|
US (1) | US8575210B2 (pt) |
EP (1) | EP2300424B1 (pt) |
JP (1) | JP5396650B2 (pt) |
KR (1) | KR101606184B1 (pt) |
CN (1) | CN102112441B (pt) |
AR (1) | AR072718A1 (pt) |
AT (1) | ATE541831T1 (pt) |
AU (1) | AU2009269842B2 (pt) |
BR (1) | BRPI0915627A8 (pt) |
CA (1) | CA2730302C (pt) |
CY (1) | CY1112638T1 (pt) |
DK (1) | DK2300424T3 (pt) |
EA (1) | EA018079B1 (pt) |
ES (1) | ES2381180T3 (pt) |
FR (1) | FR2933609B1 (pt) |
HK (1) | HK1154852A1 (pt) |
HR (1) | HRP20120231T1 (pt) |
IL (1) | IL210386A (pt) |
MX (1) | MX2011000353A (pt) |
MY (1) | MY155959A (pt) |
PL (1) | PL2300424T3 (pt) |
PT (1) | PT2300424E (pt) |
SA (1) | SA109300453B1 (pt) |
SI (1) | SI2300424T1 (pt) |
TW (1) | TWI414289B (pt) |
UA (1) | UA102397C2 (pt) |
WO (1) | WO2010004221A2 (pt) |
ZA (1) | ZA201100041B (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2955108B1 (fr) * | 2010-01-08 | 2012-03-16 | Fournier Lab Sa | Utilisation de derives de pyrrolopyridine comme activateurs de nurr-1, pour le traitement de la maladie de parkinson |
EP2487159A1 (en) * | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
WO2013029338A1 (en) * | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
CN111655255B (zh) | 2017-11-15 | 2024-03-08 | 韩国生命工学研究院 | 包含二萜类化合物的用于预防或治疗神经退行性疾病的组合物 |
KR102059160B1 (ko) | 2017-11-15 | 2019-12-24 | 한국생명공학연구원 | 다프난 또는 포볼 다이터펜계 화합물을 포함하는 신경퇴행성 질환 예방 또는 치료용 조성물 |
KR101964889B1 (ko) | 2017-11-17 | 2019-04-02 | 한국생명공학연구원 | 다이터펜계 화합물을 포함하는 신경퇴행성 질환 예방 또는 치료용 조성물 |
KR20240020098A (ko) | 2022-08-05 | 2024-02-14 | 엠테라파마 주식회사 | 다이터펜계 화합물을 포함하는 신경퇴행성 질환 예방 또는 치료용 조성물 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60204674T2 (de) * | 2001-03-14 | 2006-05-18 | Eli Lilly And Co., Indianapolis | Retinoid x rezeptormodulatoren |
GB0119911D0 (en) * | 2001-08-15 | 2001-10-10 | Novartis Ag | Organic Compounds |
GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
EP1689389A4 (en) * | 2003-12-04 | 2009-06-17 | Nat Health Research Institutes | Indole compounds |
FR2890071B1 (fr) * | 2005-08-30 | 2007-11-09 | Fournier Sa Sa Lab | Nouveaux composes de l'indole |
FR2903106B1 (fr) | 2006-07-03 | 2010-07-30 | Sanofi Aventis | Utilisations de 2-benzoyl-imidazopyridines en therapeutique |
FR2903107B1 (fr) | 2006-07-03 | 2008-08-22 | Sanofi Aventis Sa | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
FR2903105A1 (fr) | 2006-07-03 | 2008-01-04 | Sanofi Aventis Sa | Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique |
FR2906250B1 (fr) * | 2006-09-22 | 2008-10-31 | Sanofi Aventis Sa | Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique |
-
2008
- 2008-07-10 FR FR0854712A patent/FR2933609B1/fr not_active Expired - Fee Related
-
2009
- 2009-07-08 SA SA109300453A patent/SA109300453B1/ar unknown
- 2009-07-08 AR ARP090102577A patent/AR072718A1/es unknown
- 2009-07-09 DK DK09784501.0T patent/DK2300424T3/da active
- 2009-07-09 WO PCT/FR2009/051372 patent/WO2010004221A2/fr active Application Filing
- 2009-07-09 JP JP2011517215A patent/JP5396650B2/ja not_active Expired - Fee Related
- 2009-07-09 CA CA2730302A patent/CA2730302C/fr not_active Expired - Fee Related
- 2009-07-09 AT AT09784501T patent/ATE541831T1/de active
- 2009-07-09 SI SI200930209T patent/SI2300424T1/sl unknown
- 2009-07-09 US US13/003,554 patent/US8575210B2/en not_active Expired - Fee Related
- 2009-07-09 AU AU2009269842A patent/AU2009269842B2/en not_active Ceased
- 2009-07-09 ES ES09784501T patent/ES2381180T3/es active Active
- 2009-07-09 BR BRPI0915627A patent/BRPI0915627A8/pt not_active IP Right Cessation
- 2009-07-09 UA UAA201100224A patent/UA102397C2/ru unknown
- 2009-07-09 CN CN2009801269277A patent/CN102112441B/zh not_active Expired - Fee Related
- 2009-07-09 KR KR1020117000129A patent/KR101606184B1/ko not_active IP Right Cessation
- 2009-07-09 EP EP09784501A patent/EP2300424B1/fr not_active Not-in-force
- 2009-07-09 MY MYPI2011000084A patent/MY155959A/en unknown
- 2009-07-09 EA EA201170150A patent/EA018079B1/ru not_active IP Right Cessation
- 2009-07-09 MX MX2011000353A patent/MX2011000353A/es active IP Right Grant
- 2009-07-09 PL PL09784501T patent/PL2300424T3/pl unknown
- 2009-07-09 PT PT09784501T patent/PT2300424E/pt unknown
- 2009-07-10 TW TW098123503A patent/TWI414289B/zh not_active IP Right Cessation
-
2010
- 2010-12-30 IL IL210386A patent/IL210386A/en not_active IP Right Cessation
-
2011
- 2011-01-03 ZA ZA2011/00041A patent/ZA201100041B/en unknown
- 2011-08-29 HK HK11109072.9A patent/HK1154852A1/xx not_active IP Right Cessation
-
2012
- 2012-03-13 HR HR20120231T patent/HRP20120231T1/hr unknown
- 2012-03-14 CY CY20121100267T patent/CY1112638T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0915627A8 (pt) | Compostos derivados de indol, composições farmacêuticas que os contêm, e seus usos | |
BRPI1011657A2 (pt) | derivados aminopropiônicos substituídos como inibidores de neprilisina | |
MA38461A1 (fr) | Inhibiteurs de la voie de la kynurénine | |
BRPI0515851A (pt) | composto de pirimidona | |
ATE517882T1 (de) | Chinolinderivate | |
BRPI0415746A (pt) | derivados de amida | |
EA200801826A1 (ru) | Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения | |
CO6470846A2 (es) | Derivados aminobut´ricos sustituidos como inhibidores de neprilisina | |
EA201000805A1 (ru) | Бис-(сульфониламино)производные в терапии 066 | |
UY30438A1 (es) | Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos | |
UY32156A (es) | Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones. | |
BR112014009717A2 (pt) | "derivados de 2-(fenil ou pirid-3-il)aminopirimidina, seus usos, e composição farmacêutica" | |
MA33734B1 (fr) | N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase | |
EA200602260A1 (ru) | Применение замещенных хинолиновых производных для лечения заболеваний, вызываемых микобактериями, резистентными к лекарственным средствам | |
EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
SV2011003912A (es) | Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1 | |
BRPI0515628A (pt) | composto de 2-morfolina-4-pirimidona | |
NO20092535L (no) | Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol | |
BR112015031878A2 (pt) | composição farmacêutica | |
BR112014017985A8 (pt) | Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer | |
MA32929B1 (fr) | Lactames en tant qu'inhibiteurs de bêta-sécrétase | |
BRPI0706992C8 (pt) | composto de fórmula (i) e formulação farmacêutica | |
BR112015019369A2 (pt) | derivados de ácido bisfenil butanóico substituídos como inibidores de nep (endopeptidase neutra) | |
BR112013025128A2 (pt) | derivados de pirrol como moduladores de receptor de acetilcolina nicotínico para uso no tratamento de distúrbios neurodegenenerativos tal como doença de alzheimer e doença de parkinson | |
UY32055A (es) | Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: INVENTIVA (FR) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2470 DE 08-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |